You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
榮昌生物(688331.SH):公司核心藥品專利獲得期限補償

格隆匯6月13日丨榮昌生物(688331.SH)公佈,公司收到國家知識產權局下發的《藥品專利權期限補償審批決定》,專利名稱:優化的TACI-Fc融合蛋白,涉及藥品:注射用泰它西普。

按照中國專利法及其實施細則相關規定,決定給予該專利藥品專利權期限補償,補償天數1827天,原專利權期滿終止日2027年6月15日,現專利權期滿終止日2032年6月15日。藥品專利權期限補償期間,其保護範圍限於國務院藥品監督管理部門批準上市的新藥,且限於該新藥經批準的適應症相關技術方案。

上述藥品專利權期限補償的取得符合公司發展戰略規劃,專利保護期延長至2032年,爲公司核心產品提供額外5年的市場保護,將顯著提升公司藥品在中國市場的獨佔銷售窗口期,有利於中長期業績增長,提升公司的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account